Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""pharmacokinetics"" wg kryterium: Temat


Tytuł:
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.
Autorzy:
Darlow CA; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool, UK.
Parrott N; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Peck RW; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool, UK.; Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Hope W; Antimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology, University of Liverpool, Liverpool, UK.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 464-475. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Journal Article
MeSH Terms:
Fosfomycin*/pharmacokinetics
Neonatal Sepsis*/drug therapy
Humans ; Infant, Newborn ; Amikacin/pharmacokinetics ; Anti-Bacterial Agents/pharmacokinetics ; Microbial Sensitivity Tests ; Multicenter Studies as Topic ; Clinical Trials as Topic
Czasopismo naukowe
Tytuł:
External validation of the modified Marsh and Schnider models for medium-chain triglyceride propofol in target-controlled infusion anesthesia.
Autorzy:
Lee S; Department of Anesthesiology and Pain Medicine, Chonnam University Hospital, Gwangju, South Korea.; Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, 160, Baekseo-ro, Dong-gu, Gwangju, South Korea.
Kang D; Department of Anesthesiology and Pain Medicine, Chonnam University Hospital, Gwangju, South Korea.
Song E; Department of Anesthesiology and Pain Medicine, Chonnam University Hospital, Gwangju, South Korea.
Yoo S; Department of Anesthesiology and Pain Medicine, Chonnam University Hospital, Gwangju, South Korea.
Jeong S; Department of Anesthesiology and Pain Medicine, Chonnam University Hospital, Gwangju, South Korea. .; Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, 160, Baekseo-ro, Dong-gu, Gwangju, South Korea. .
Pokaż więcej
Źródło:
BMC anesthesiology [BMC Anesthesiol] 2024 Feb 23; Vol. 24 (1), pp. 70. Date of Electronic Publication: 2024 Feb 23.
Typ publikacji:
Journal Article
MeSH Terms:
Propofol*/pharmacokinetics
Adult ; Humans ; Anesthetics, Intravenous/pharmacokinetics ; Reproducibility of Results ; Wetlands ; Infusions, Intravenous ; Anesthesia, General/methods ; Triglycerides
Czasopismo naukowe
Tytuł:
The effect of genetic variants in the transcription factor TSPYL family on the CYP3A4 mediated cyclosporine metabolism in kidney transplant patients.
Autorzy:
Zhai Q; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
van Gelder T; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
van der Lee M; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Sanders JS; Department of Nephrology, University Medical Center Groningen, Groningen, The Netherlands.
Bemelman FJ; Department of Nephrology, Academic Medical Center, Amsterdam, The Netherlands.
de Fijter JW; Department of Nephrology, Antwerp University Medical Center, Edegem, Belgium.
Klein K; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.; Departments of Clinical Pharmacology, and Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany.
Schwab M; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.; Departments of Clinical Pharmacology, and Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany.
Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2024 Feb; Vol. 17 (2), pp. e13729.
Typ publikacji:
Journal Article
MeSH Terms:
Cyclosporine*/pharmacokinetics
Kidney Transplantation*/adverse effects
Male ; Humans ; Cytochrome P-450 CYP3A/genetics ; Immunosuppressive Agents/pharmacokinetics ; Transcription Factors/genetics ; Prospective Studies ; Genotype ; Polymorphism, Single Nucleotide
Czasopismo naukowe
Tytuł:
Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side.
Autorzy:
Terrier J; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.
Gaspar F; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Gosselin P; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
Raboud O; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Lenoir C; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.
Rollason V; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.
Csajka C; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Samer C; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Fontana P; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Angiology and Haemostasis, Geneva University Hospitals, Geneva, Switzerland.
Daali Y; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Clinical Pharmacology and Toxicology Service, Anesthesiology, Pharmacology and Intensive Care Department, Geneva University Hospitals, Geneva, Switzerland.
Reny JL; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Pokaż więcej
Corporate Authors:
OptimAT study group
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Dec; Vol. 12 (12), pp. 1872-1883. Date of Electronic Publication: 2023 Oct 04.
Typ publikacji:
Journal Article
MeSH Terms:
Rivaroxaban*/pharmacokinetics
Pyrazoles*/pharmacokinetics
Humans ; Aged ; Pyridones/pharmacokinetics ; Administration, Oral ; Anticoagulants
Czasopismo naukowe
Tytuł:
The Use of Cyclodextrin Inclusion Complexes to Increase the Solubility and Pharmacokinetic Profile of Albendazole.
Autorzy:
Ding Y; College of Science and Technology, Wenzhou-Kean University, Wenzhou 325000, China.; Wenzhou Municipal Key Laboratory for Applied Biomedical and Biopharmaceutical Informatics, Wenzhou-Kean University, Wenzhou 325060, China.; Zhejiang Bioinformatics International Science and Technology Cooperation Center, Wenzhou-Kean University, Wenzhou 325060, China.; Dorothy and George Hennings College of Science, Mathematics and Technology, Kean University, 1000 Morris Ave, Union, NJ 07083, USA.
Zhang Z; Life Science Department, Foshan University, Foshan 528000, China.
Ding C; Keck School of Medicine of USC, Los Angeles, CA 90089, USA.
Xu S; Life Science Department, Foshan University, Foshan 528000, China.
Xu Z; College of Science and Technology, Wenzhou-Kean University, Wenzhou 325000, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Oct 27; Vol. 28 (21). Date of Electronic Publication: 2023 Oct 27.
Typ publikacji:
Journal Article
MeSH Terms:
Cyclodextrins*/pharmacokinetics
Anthelmintics*/pharmacokinetics
Animals ; Humans ; Albendazole/pharmacokinetics ; Solubility ; Water
Czasopismo naukowe
Tytuł:
Interspecies and in vitro-in vivo scaling for quantitative modeling of whole-body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin.
Autorzy:
Catozzi S; Institut Curie, Inserm U900, MINES ParisTech, CBIO - Centre for Computational Biology, PSL Research University, Saint-Cloud, France.
Hill R; EPSRC and MRC Centre for Doctoral Training in Mathematics for Real-World Systems, University of Warwick, Coventry, UK.
Li XM; UPR 'Chronotherapy, Cancers and Transplantation,' Faculty of Medicine, Université Paris-Saclay, Villejuif, France.
Dulong S; Institut Curie, Inserm U900, MINES ParisTech, CBIO - Centre for Computational Biology, PSL Research University, Saint-Cloud, France.; UPR 'Chronotherapy, Cancers and Transplantation,' Faculty of Medicine, Université Paris-Saclay, Villejuif, France.
Collard E; CEA, CNRS, NIMBE, Université Paris-Saclay, Gif-sur-Yvette, France.
Ballesta A; Institut Curie, Inserm U900, MINES ParisTech, CBIO - Centre for Computational Biology, PSL Research University, Saint-Cloud, France.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Feb; Vol. 12 (2), pp. 221-235. Date of Electronic Publication: 2022 Dec 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/pharmacokinetics
Humans ; Rats ; Mice ; Animals ; Oxaliplatin ; Models, Biological ; Pharmacokinetics
Czasopismo naukowe
Tytuł:
Single protein encapsulated SN38 for tumor-targeting treatment.
Autorzy:
Yu C; Department of Chemistry, California Institute of Technology, Pasadena, CA, 91125, USA. .; Sunstate Biosciences, LLC, 870 S. Myrtle Ave, Monrovia, CA, 91016, USA. .
Huang F; Department of Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, MS, 39406, USA. .
Wang K; Sunstate Biosciences, LLC, 870 S. Myrtle Ave, Monrovia, CA, 91016, USA.
Liu M; Sunstate Biosciences, LLC, 870 S. Myrtle Ave, Monrovia, CA, 91016, USA.
Chow WA; Division of Hematology/Oncology, Department of Medicine, UCI Health, Orange, CA, 92868, USA.
Ling X; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14263, USA.; Canget BioTekpharma, LLC, 701 Ellicott Street, Buffalo, NY, 14203, USA.
Li F; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
Causey JL; Department of Computer Sciences, Arkansas State University, Jonesboro, AR, 72467, USA.
Huang X; Department of Computational Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Cook-Wiens G; Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, CA, 90048, USA.
Cui X; Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, 90048, USA. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Dec 10; Vol. 21 (1), pp. 897. Date of Electronic Publication: 2023 Dec 10.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Colorectal Neoplasms*/drug therapy
Antineoplastic Agents, Phytogenic*/pharmacokinetics
Humans ; Mice ; Animals ; Irinotecan/therapeutic use ; Irinotecan/pharmacokinetics ; Xenograft Model Antitumor Assays ; Camptothecin/pharmacology ; Camptothecin/therapeutic use ; Disease Models, Animal ; Water ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention.
Autorzy:
Leung E; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
Cottrell ML; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
Sykes C; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
White N; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Kashuba ADM; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Dumond JB; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Dec; Vol. 12 (12), pp. 1922-1930. Date of Electronic Publication: 2023 Oct 09.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-HIV Agents*/pharmacokinetics
HIV Infections*/drug therapy
HIV Infections*/prevention & control
Pre-Exposure Prophylaxis*
Female ; Humans ; Tenofovir/pharmacokinetics ; Emtricitabine/therapeutic use
Czasopismo naukowe
Tytuł:
Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab.
Autorzy:
Miguel-Lillo B; Medical Department, mAbxience Research S.L., Madrid, Spain.
Sánchez-Vidaurre S; Medical Department, mAbxience Research S.L., Madrid, Spain.
Pérez Díaz L; Medical Department, mAbxience Research S.L., Madrid, Spain.
Paravisini A; Medical Department, mAbxience Research S.L., Madrid, Spain.
Pokaż więcej
Źródło:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2023 Dec; Vol. 11 (6), pp. e01139.
Typ publikacji:
Journal Article; Meta-Analysis
MeSH Terms:
Biosimilar Pharmaceuticals*/adverse effects
Biosimilar Pharmaceuticals*/pharmacokinetics
Humans ; Antibodies, Monoclonal ; Area Under Curve ; Bevacizumab/adverse effects ; Bevacizumab/pharmacokinetics ; Therapeutic Equivalency
Czasopismo naukowe
Tytuł:
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX.
Autorzy:
Liao MZ; Genentech, Inc., South San Francisco, California, USA.
Deng R; Genentech, Inc., South San Francisco, California, USA.
Gibiansky L; QuantPharm LLC, North Potomac, Maryland, USA.
Lu T; Genentech, Inc., South San Francisco, California, USA.
Agarwal P; Genentech, Inc., South San Francisco, California, USA.
Dere R; Genentech, Inc., South San Francisco, California, USA.
Lee C; Genentech, Inc., South San Francisco, California, USA.
Hirata J; Genentech, Inc., South San Francisco, California, USA.
Herbaux C; CHU de Montpellier, Montpellier, France.
Salles G; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Li C; Genentech, Inc., South San Francisco, California, USA.
Miles D; Genentech, Inc., South San Francisco, California, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Dec; Vol. 16 (12), pp. 2744-2755. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article
MeSH Terms:
Immunoconjugates*/pharmacokinetics
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/pathology
Humans ; Antibodies, Monoclonal/pharmacokinetics ; Asia ; Clinical Trials, Phase III as Topic
Czasopismo naukowe
Tytuł:
Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study.
Autorzy:
Gaspar F; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.
Terrier J; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Clinical Pharmacology and Toxicology, Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine Department, Geneva University Hospitals, Geneva, Switzerland.
Favre S; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.
Gosselin P; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Fontana P; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Angiology and Haemostasis, Geneva University Hospitals, Geneva, Switzerland.
Daali Y; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Clinical Pharmacology and Toxicology, Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine Department, Geneva University Hospitals, Geneva, Switzerland.
Lenoir C; Division of Clinical Pharmacology and Toxicology, Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine Department, Geneva University Hospitals, Geneva, Switzerland.
Samer CF; Division of Clinical Pharmacology and Toxicology, Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine Department, Geneva University Hospitals, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Rollason V; Division of Clinical Pharmacology and Toxicology, Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine Department, Geneva University Hospitals, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Reny JL; Division of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Platelet Group, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Csajka C; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.
Guidi M; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Lausanne, Switzerland.; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Oct; Vol. 12 (10), pp. 1541-1552. Date of Electronic Publication: 2023 Sep 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Models, Biological*
Pyridones*/pharmacokinetics
Humans ; Pyrazoles/pharmacokinetics ; Area Under Curve
Czasopismo naukowe
Tytuł:
Pharmacokinetic analysis across studies to drive knowledge-integration: A tutorial on individual patient data meta-analysis (IPDMA).
Autorzy:
van Wijk RC; University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
Imperial MZ; University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
Savic RM; University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
Solans BP; University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, USA.; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Sep; Vol. 12 (9), pp. 1187-1200. Date of Electronic Publication: 2023 Jun 11.
Typ publikacji:
Journal Article
MeSH Terms:
Databases, Factual*
Pharmacokinetics*
Meta-Analysis as Topic*
Humans ; Drug Development
Czasopismo naukowe
Tytuł:
Bioavailability of Cariban Capsules: A Modified-Release Fixed-Dose Combination of Doxylamine and Pyridoxine to Relieve Nausea and Vomiting During Pregnancy.
Autorzy:
Saz-Leal P; Medical Department, ITF Research Pharma S.L.U., Alcobendas, Spain.
Zamorano-Domínguez L; R&D Department, ITF Research Pharma S.L.U., Alcobendas, Spain.
Frías J; Clinical Pharmacology Department, La Paz University Hospital, School of Medicine, IdiPAZ, Autonomous University of Madrid, Madrid, Spain.
Guerra P; Clinical Pharmacology Department, La Paz University Hospital, School of Medicine, IdiPAZ, Autonomous University of Madrid, Madrid, Spain.
Saura-Valls M; Inibsa Ginecologia S.A, Barcelona, Spain.
Roca-Juanes R; Inibsa Ginecologia S.A, Barcelona, Spain.
Nebot-Troyano J; Inibsa Ginecologia S.A, Barcelona, Spain.
García-Aguilar E; Medical Department, ITF Research Pharma S.L.U., Alcobendas, Spain.
Vilchez T; Medical Department, ITF Research Pharma S.L.U., Alcobendas, Spain.
Urso K; R&D Department, ITF Research Pharma S.L.U., Alcobendas, Spain. .
Pokaż więcej
Źródło:
Drugs in R&D [Drugs R D] 2023 Jun; Vol. 23 (2), pp. 185-195. Date of Electronic Publication: 2023 Jun 15.
Typ publikacji:
Journal Article
MeSH Terms:
Antiemetics*/pharmacokinetics
Antiemetics*/therapeutic use
Pregnancy Complications*/drug therapy
Adult ; Female ; Humans ; Pregnancy ; Biological Availability ; Capsules ; Delayed-Action Preparations ; Doxylamine/pharmacokinetics ; Drug Combinations ; Nausea ; Pyridoxine/pharmacokinetics ; Pyridoxine/therapeutic use ; Vomiting/drug therapy
Czasopismo naukowe
Tytuł:
Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
Autorzy:
Mulford DJ; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Ramsden D; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Zhang L; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Michon I; Certara, Sheffield, UK.
Leifke E; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Smith N; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Jones HM; Certara, Sheffield, UK.
Scarpignato C; United Campus of Malta, Msida, Malta.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Apr; Vol. 12 (4), pp. 532-544. Date of Electronic Publication: 2023 Mar 10.
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics
Cytochrome P-450 CYP3A Inducers*/pharmacokinetics
Humans ; Midazolam/pharmacokinetics ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Models, Biological
Czasopismo naukowe
Tytuł:
Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia.
Autorzy:
Chala A; Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.; Department of Global Public Health, Karolinska Institutet, Widerströmska Huset, Stockholm, Sweden.
Kitabi EN; Division of Pharmacometrics, Office of Clinical Pharmacology, Food and Drugs Administration, Silver Spring, Maryland, USA.
Ahmed JH; Department of Pharmacy, Jimma University, Jimma, Ethiopia.
Tadesse BT; Department of Global Public Health, Karolinska Institutet, Widerströmska Huset, Stockholm, Sweden.; Department of Pediatrics, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia.
Chaka TE; Department of Pediatrics and Child Health, Adama Hospital Medical College, Adama, Ethiopia.
Makonnen E; Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.; Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Aklillu E; Department of Global Public Health, Karolinska Institutet, Widerströmska Huset, Stockholm, Sweden.; Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Jun; Vol. 12 (6), pp. 783-794. Date of Electronic Publication: 2023 Mar 23.
Typ publikacji:
Journal Article
MeSH Terms:
HIV-1*
Anti-HIV Agents*/therapeutic use
Anti-HIV Agents*/pharmacokinetics
HIV Infections*/drug therapy
HIV Infections*/genetics
Humans ; Child ; Cytochrome P-450 CYP2B6/genetics ; Ethiopia ; Benzoxazines/therapeutic use ; Benzoxazines/pharmacokinetics ; Cyclopropanes ; Body Weight ; Genotype
Czasopismo naukowe
Tytuł:
Age associations with tacrolimus and mycophenolic acid pharmacokinetics in stable Black and White kidney transplant recipients: Implications for health inequities.
Autorzy:
Tornatore KM; Transplantation Immunosuppressive Pharmacology Research Program, Translational Pharmacology Research Core, Department of Pharmacy Practice School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.; Department of Medicine, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Attwood K; Department of Biostatistics, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA.
Venuto RC; Department of Medicine, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.; Division of Nephrology, Erie County Medical Center, University at Buffalo, Buffalo, New York, USA.
Murray B; Department of Medicine, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.; Division of Nephrology, Erie County Medical Center, University at Buffalo, Buffalo, New York, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 May; Vol. 16 (5), pp. 861-871. Date of Electronic Publication: 2023 Apr 13.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Tacrolimus*/adverse effects
Tacrolimus*/pharmacokinetics
Kidney Transplantation*/adverse effects
Adult ; Middle Aged ; Aged ; Humans ; Mycophenolic Acid/adverse effects ; Area Under Curve ; Immunosuppressive Agents/pharmacokinetics ; Health Inequities
Czasopismo naukowe
Tytuł:
Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants.
Autorzy:
Barth A; GSK, Collegeville, Pennsylvania, USA.; Present affiliation: Global Blood Therapeutics, San Francisco, California, USA.
Hossain M; GSK, Collegeville, Pennsylvania, USA.; Present affiliation: Servier Pharmaceuticals, Boston, Massachusetts, USA.
Perry CR; GSK, Collegeville, Pennsylvania, USA.
Gross AS; GSK R&D, Sydney, AU.
Ogura H; GSK, Tokyo, Japan.
Shabbir S; GSK, Stevenage, UK.
Thomas S; GSK, Collegeville, Pennsylvania, USA.
Dumont EF; GSK, Collegeville, Pennsylvania, USA.; Present affiliation: Boston Pharmaceuticals, Cambridge, Massachusetts, USA.
Brimhall DB; PPD, Las Vegas, Nevada, USA.
Srinivasan M; GSK, Collegeville, Pennsylvania, USA.
Swift B; GSK, Durham, North Carolina, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Jan; Vol. 12 (1), pp. 38-56. Date of Electronic Publication: 2022 Dec 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Acenaphthenes*/pharmacokinetics
Heterocyclic Compounds, 3-Ring*/pharmacokinetics
Humans ; Healthy Volunteers ; Anti-Bacterial Agents/pharmacokinetics
Czasopismo naukowe
Tytuł:
Statistical optimization of bile salt deployed nanovesicles as a potential platform for oral delivery of piperine: accentuated antiviral and anti-inflammatory activity in MERS-CoV challenged mice.
Autorzy:
Zakaria MY; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Port Said University, Port Said, Egypt.
Fayad E; Department of Biotechnology, Faculty of Sciences, Taif University, Taif, Saudi Arabia.
Althobaiti F; Department of Biotechnology, Faculty of Sciences, Taif University, Taif, Saudi Arabia.
Zaki I; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Port Said University, Port Said, Egypt.
Abu Almaaty AH; Department of Zoology, Faculty of Science, Port Said University, Port Said, Egypt.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2021 Dec; Vol. 28 (1), pp. 1150-1165.
Typ publikacji:
Journal Article
MeSH Terms:
Alkaloids*/administration & dosage
Alkaloids*/pharmacokinetics
Benzodioxoles*/administration & dosage
Benzodioxoles*/pharmacokinetics
Piperidines*/administration & dosage
Piperidines*/pharmacokinetics
Polyunsaturated Alkamides*/administration & dosage
Polyunsaturated Alkamides*/pharmacokinetics
Bile Acids and Salts/*pharmacokinetics
Drug Delivery Systems/*methods
Middle East Respiratory Syndrome Coronavirus/*drug effects
Administration, Oral ; Animals ; Antiviral Agents/administration & dosage ; Antiviral Agents/pharmacokinetics ; Biological Availability ; Cytochrome P-450 Enzyme Inhibitors/administration & dosage ; Cytochrome P-450 Enzyme Inhibitors/pharmacokinetics ; Drug Liberation ; Liposomes ; Mice ; Molecular Docking Simulation ; Nanostructures ; Plants, Medicinal ; Surface-Active Agents/pharmacokinetics
Czasopismo naukowe
Tytuł:
Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia.
Autorzy:
Mostafa S; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; MyDNA Life Australia Limited, Victoria, Australia.
Rafizadeh R; BC Mental Health and Substance Use Services, BC Psychosis Program, Lower Mainland Pharmacy Services, Vancouver, British Columbia, Canada.
Polasek TM; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; Certara, Princeton, New Jersey, USA.; Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Bousman CA; Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Departments of Medical Genetics, Psychiatry, Physiology and Pharmacology, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Rostami-Hodjegan A; Centre for Applied Pharmacokinetic Research (CAPKR), School of Health Sciences, University of Manchester, Manchester, UK.; Simcyp Division, Certara UK Limited, Sheffield, UK.
Stowe R; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.; Djavid Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Neurology (Medicine), University of British Columbia, Vancouver, British Columbia, Canada.
Carrion P; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Sheffield LJ; MyDNA Life Australia Limited, Victoria, Australia.
Kirkpatrick CMJ; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 424-436. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Clozapine*/pharmacokinetics
Clozapine*/therapeutic use
Antipsychotic Agents*/pharmacokinetics
Schizophrenia*/drug therapy
Humans ; Fluvoxamine ; Schizophrenia, Treatment-Resistant
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies